Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Lancome Vitalite Douceur body care collection comprises three new products -- Douceur Pure Cleansing Body Milk, Gommage Pur Exfoliating Body Gel and Energibuste Firming-Toning Bust Treatment; two reformulated and repackaged products -- Savon Fraichelle Invigorating Body Cleansing Gel and Exfoliant Fraichelle invigorating Body Scrub; and two existing products -- Stimulative Dual Action Body Creme and Hydra-Balance Essential Hydrating Body Lotion. All of the items contain magnesium, which combats free radicals; essential fatty acids, said to "contribute to a sort, supple and radiant skin"; and provitamin B[5], which encourages moisture recovery, according to the firm. The new and existing items will be presented together under the Vitalite Douceur name beginning in April. Suggested retail prices for the products range from $20 for a 6.8 oz. tube of Savon Fraichelle to a 6.8 oz. jar of Stimulative Dual Action Body Creme

You may also be interested in...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts